Drugs / Neltependocel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06041256 | Oct 2023 → Oct 2024 | corneal edema | Aurion Biotech | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-18 | Aurion Biotech | Results Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months aurionbiotech.com ↗
Aurion Biotech , a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12-month results from the company’s Phase 1/2 CLARA trial, which evaluated the safety, efficacy and tolerability of AURN001 (neltependocel [human corneal endothelial cells] in combination with Y-27632 rho-kinase inhibitor) in patients with corneal edema secondary to corneal endothelial dysfunction. |
| 2024-09-15 | Aurion Biotech | Regulatory Aurion Biotech Launches Vyznova® in Japan for the Treatment of Bullous Keratopathy of the Cornea aurionbiotech.com ↗
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced the commercial launch of Vyznova® (generic name: neltependocel ) in Japan, for the treatment of bullous keratopathy of the cornea. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-18 | Aurion Biotech | Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months aurionbiotech.com ↗ |
| 2024-09-15 | Aurion Biotech | Aurion Biotech Launches Vyznova® in Japan for the Treatment of Bullous Keratopathy of the Cornea aurionbiotech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neltependocel | “Neltependocel - High” NCT06041256 ↗ |
| Modality | Cell therapy | — CHEMBL5314695 ↗ |